|
Real-time Estimate
Cboe BZX
22:38:11 29/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 6.955 USD | -2.45% |
|
+7.37% | +122.61% |
| 10-25 | Agenus Inc. Reports Early Phase 2 Results From dMMR Colon Cancer Cohort Of NEOASIS Study | CI |
| 10-08 | Agenus Gets Armenia Approval for Botensilimab-Balstilimab Combination | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 321M | - | - | - | ||
| 64.14B | |||||
| 55.53B | |||||
| 53.03B | |||||
| 45.99B | |||||
| 42.45B |
- Stock Market
- Stocks
- AGEN Stock
- Charts Agenus Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
